Nordic Life Science 1
T E X T b y M AL IN O T M ANI J O I N I NG F ORCE
S Ulf Hannelius, CEO, Diamyd Medical named CHO CORE, is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms. Funded by the Novo Nordisk Foundation, NBF was established in 2012 at the Technical University of Denmark (DTU). “We are excited to join forces UME Å acquired for a purchase price of 24.5 million SEK and comprises approximately 20,000 square feet, including the 10,000 square feet that Diamyd Medical rents today, as well as 90,000 square feet of land area. “The manufacturing facility is a crucial investment for the future and the acquisition gives us further opportunities to scale up and expand our manufacturing activities,” says Ulf Hannelius, CEO, Diamyd Medical. with NBF and to be able to expand our offering and capacity to clients seeking mammalian cell line development and production capabilities for recombinant proteins,” says Jette Asboe Lassen, CBO, Bioneer. This collaboration will enable Bioneer to offer end-to-end nonGMP production of recombinant proteins utilizing both microbial and mammalian expression platforms, it states. NBF brings broad experience in CHO cell line engineering and expert understanding of stable protein expression in CHO cells. Bioneer brings nearly 40 years of commercial and scientific experience creating customized service solutions in the field of expression and production of special proteins and antibodies. Jette Asboe Lassen, CBO, Bioneer NORDIC LIFE SCIENCE 9